Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04134728
Registration number
NCT04134728
Ethics application status
Date submitted
18/10/2019
Date registered
22/10/2019
Date last updated
17/07/2023
Titles & IDs
Public title
Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors
Query!
Scientific title
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
Query!
Secondary ID [1]
0
0
202018
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
contRAst 3
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Condition category
Condition code
Musculoskeletal
0
0
0
0
Query!
Osteoarthritis
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Rheumatoid arthritis
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - GSK3196165 (Otilimab)
Other interventions - Sarilumab
Treatment: Drugs - Placebo to GSK3196165/ Sarilumab
Treatment: Drugs - csDMARDs
Experimental: GSK3196165 90 mg - Entire treatment period (24 Weeks): GSK3196165 90 mg SC injection once weekly. Participants will also receive a stable dose of csDMARD(s) as standard of care (SoC).
Experimental: GSK3196165 150 mg - Entire treatment period (24 Weeks): GSK3196165 150 mg SC injection once weekly. Participants will also receive a stable dose of csDMARD(s) as SoC.
Active Comparator: Sarilumab 200 mg - Entire treatment period (24 Weeks): Sarilumab 200 mg SC injection every other week + placebo SC injection in the intervening weeks. Participants will also receive a stable dose of csDMARD(s) as SoC.
Placebo Comparator: Placebo sequence 1 - From Week 0-11: Placebo SC injection once weekly. From Week 12 onwards: GSK3196165 90 mg SC injection once weekly. Participants will also receive a stable dose of csDMARD(s) as SoC.
Placebo Comparator: Placebo sequence 2 - From Week 0-11: Placebo SC injection once weekly. From Week 12 onwards: GSK3196165 150 mg SC injection once weekly. Participants will also receive a stable dose of csDMARD(s) as SoC.
Placebo Comparator: Placebo sequence 3 - From Week 0-11: Placebo SC injection once weekly. From Week 12 onwards: Sarilumab 200 mg SC injection every other week + placebo SC injection in the intervening weeks. Participants will also receive a stable dose of csDMARD(s) as SoC.
Other interventions: GSK3196165 (Otilimab)
GSK3196165 solution in vial/pre-filled syringe (PFS) to be administered SC.
Other interventions: Sarilumab
Sarilumab solution in PFS to be administered SC.
Treatment: Drugs: Placebo to GSK3196165/ Sarilumab
Placebo sterile 0.9 percentage (%) weight by volume (w/v) sodium chloride solution in vial/PFS to be administered SC.
Treatment: Drugs: csDMARDs
Stable dose of csDMARD(s) as SoC.
Query!
Intervention code [1]
0
0
Other interventions
Query!
Intervention code [2]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants With 20% Improvement in American College of Rheumatology Criteria (ACR20) at Week 12 Superiority Comparison With Placebo
Query!
Assessment method [1]
0
0
ACR20 is calculated as a 20% improvement from Baseline in Tender Joint Count 68 (TJC68) and Swollen Joint Count 66 (SJC66) and a 20% improvement in 3 of the following 5 measures: Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale (VAS) with values from 0=best to 100=worst), Physician Global Assessment of Arthritis Disease Activity (PhGA) (VAS with values from 0=best to 100=worst), Patient Assessment of Arthritis Pain (VAS with values from 0=no pain and 100=most severe pain), Health Assessment Questionnaire-Disability Index (HAQ-DI) (ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty) and an acute-phase reactant (high sensitivity C-reactive Protein mg/L (hsCRP)). For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [1]
0
0
Week 12
Query!
Secondary outcome [1]
0
0
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) (Versus Placebo) at Week 12
Query!
Assessment method [1]
0
0
Health Assessment Questionnaire-Disability Index (HAQ-DI) is a 20-question instrument that assesses the difficulty of a participant in eight domains of daily living activities: Dressing & grooming, Arising, Eating, Walking, Hygiene, Reach, Grip, Common daily activities. Overall HAQ-DI score was computed as the sum of the domain scores divided by the number of domains answered. The total possible score ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty. Higher overall score indicates greater disability. A negative change from baseline indicates an improvement. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [1]
0
0
Baseline (Day 01) and Week 12
Query!
Secondary outcome [2]
0
0
Percentage of Participants With Clinical Disease Activity Index (CDAI) Total Score <=10 (CDAI Low Disease Activity [LDA]) at Week 12
Query!
Assessment method [2]
0
0
Clinical Disease Activity Index (CDAI) total score is a composite score consisting of the sum of Swollen Joint Count 28 (TJC28), Tender Joint Count 28 (TJC28), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst) and Physician Global Assessment of Arthritis Disease Activity (PhGA) (visual analogue scale with values from 0=best to 100=worst). CDAI total score ranges from 0 to 76 with higher values representing higher disease activity. Low disease activity (LDA) is achieved when CDAI total score <=10. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [2]
0
0
Week 12
Query!
Secondary outcome [3]
0
0
Percentage of Participants With CDAI Total Score <=10 (CDAI LDA) at Week 24 for Treatment Arms That Started Study Intervention From Day 1
Query!
Assessment method [3]
0
0
Clinical Disease Activity Index (CDAI) total score is a composite score consisting of the sum of Swollen Joint Count 28 (TJC28),Tender Joint Count 28 (TJC28), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst) and Physician Global Assessment of Arthritis Disease Activity (PhGA) (visual analogue scale with values from 0=best to 100=worst). CDAI total score ranges from 0 to 76 with higher values representing higher disease activity. LDA is achieved when CDAI total score <=10.
Query!
Timepoint [3]
0
0
Week 24
Query!
Secondary outcome [4]
0
0
Percentage of Participants With CDAI Total Score <=10 (CDAI LDA) at Week 24 for Placebo Switched Arms That Started Study Intervention From Week 12
Query!
Assessment method [4]
0
0
Clinical Disease Activity Index (CDAI) total score is a composite score consisting of the sum of Swollen Joint Count 28 (TJC28),Tender Joint Count 28 (TJC28), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst) and Physician Global Assessment of Arthritis Disease Activity (PhGA) (visual analogue scale with values from 0=best to 100=worst). CDAI total score ranges from 0 to 76 with higher values representing higher disease activity. LDA is achieved when CDAI total score <=10.
Query!
Timepoint [4]
0
0
Week 24
Query!
Secondary outcome [5]
0
0
Change From Baseline in CDAI Total Score at Week 12
Query!
Assessment method [5]
0
0
Clinical Disease Activity Index (CDAI) total score is a composite score consisting of the sum of Swollen Joint Count 28 (TJC28),Tender Joint Count 28 (TJC28), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst) and Physician Global Assessment of Arthritis Disease Activity (PhGA) (visual analogue scale with values from 0=best to 100=worst). CDAI total score ranges from 0 to 76 with higher values representing higher disease activity. A negative CDAI total score change from baseline indicates an improvement in disease activity. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [5]
0
0
Baseline (Day 01) and Week 12
Query!
Secondary outcome [6]
0
0
Change From Baseline in CDAI Total Score at Week 24 for Treatment Arms That Started Study Intervention From Day 1
Query!
Assessment method [6]
0
0
Clinical Disease Activity Index (CDAI) total score is a composite score consisting of the sum of Swollen Joint Count 28 (TJC28), Tender Joint Count 28 (TJC28), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst) and Physician Global Assessment of Arthritis Disease Activity (PhGA) (visual analogue scale with values from 0=best to 100=worst). CDAI total score ranges from 0 to 76 with higher values representing higher disease activity.
Query!
Timepoint [6]
0
0
Baseline (Day 01) and Week 24
Query!
Secondary outcome [7]
0
0
Change From Baseline in CDAI Total Score at Week 24 for Placebo Switched Arms That Started Study Intervention From Week 12
Query!
Assessment method [7]
0
0
Clinical Disease Activity Index (CDAI) total score is a composite score consisting of the sum of Swollen Joint Count 28 (TJC28), Tender Joint Count 28 (TJC28), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst) and Physician Global Assessment of Arthritis Disease Activity (PhGA) (visual analogue scale with values from 0=best to 100=worst). CDAI total score ranges from 0 to 76 with higher values representing higher disease activity.
Query!
Timepoint [7]
0
0
Baseline (Day 01) and Week 24
Query!
Secondary outcome [8]
0
0
Change From Baseline in Arthritis Pain Visual Analogue Scale (VAS) at Week 12
Query!
Assessment method [8]
0
0
For the Arthritis Pain VAS, participants assess the severity of their current arthritis pain using a continuous visual analogue scale (VAS) with anchors at "0" (no pain) and "100" (most severe pain). A negative change from baseline indicates an improvement. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [8]
0
0
Baseline (Day 01) and Week 12
Query!
Secondary outcome [9]
0
0
Change From Baseline in Arthritis Pain VAS at Week 24 for Treatment Arms That Started Study Intervention From Day 1
Query!
Assessment method [9]
0
0
For the Arthritis Pain VAS, participants assess the severity of their current arthritis pain using a continuous visual analogue scale (VAS) with anchors at "0" (no pain) and "100" (most severe pain). A negative change from baseline indicates an improvement.
Query!
Timepoint [9]
0
0
Baseline (Day 01) and Week 24
Query!
Secondary outcome [10]
0
0
Change From Baseline in Arthritis Pain VAS at Week 24 for Placebo Switched Arms That Started Study Intervention From Week 12
Query!
Assessment method [10]
0
0
For the Arthritis Pain VAS, participants assess the severity of their current arthritis pain using a continuous visual analogue scale (VAS) with anchors at "0" (no pain) and "100" (most severe pain). A negative change from baseline indicates an improvement.
Query!
Timepoint [10]
0
0
Baseline (Day 01) and Week 24
Query!
Secondary outcome [11]
0
0
Percentage of Participants With CDAI Total Score <=2.8 (CDAI Remission) at Week 12
Query!
Assessment method [11]
0
0
Clinical Disease Activity Index (CDAI) total score is a composite score consisting of the sum of Swollen Joint Count 28 (TJC28),Tender Joint Count 28 (TJC28), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst) and Physician Global Assessment of Arthritis Disease Activity (PhGA) (visual analogue scale with values from 0=best to 100=worst). CDAI total score ranges from 0 to 76 with higher values representing higher disease activity. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [11]
0
0
Week 12
Query!
Secondary outcome [12]
0
0
Percentage of Participants With CDAI Total Score <=2.8 (CDAI Remission) at Week 24 for Treatment Arms That Started Study Intervention From Day 1
Query!
Assessment method [12]
0
0
Clinical Disease Activity Index (CDAI) total score is a composite score consisting of the sum of Swollen Joint Count 28 (TJC28), Tender Joint Count 28 (TJC28), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst) and Physician Global Assessment of Arthritis Disease Activity (PhGA) (visual analogue scale with values from 0=best to 100=worst). CDAI total score ranges from 0 to 76 with higher values representing higher disease activity.
Query!
Timepoint [12]
0
0
Week 24
Query!
Secondary outcome [13]
0
0
Percentage of Participants With CDAI Total Score <=2.8 (CDAI Remission) at Week 24 for Placebo Switched Arms That Started Study Intervention From Week 12
Query!
Assessment method [13]
0
0
Clinical Disease Activity Index (CDAI) total score is a composite score consisting of the sum of Swollen Joint Count 28 (TJC28), Tender Joint Count 28 (TJC28), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst) and Physician Global Assessment of Arthritis Disease Activity (PhGA) (visual analogue scale with values from 0=best to 100=worst). CDAI total score ranges from 0 to 76 with higher values representing higher disease activity.
Query!
Timepoint [13]
0
0
Week 24
Query!
Secondary outcome [14]
0
0
Percentage of Participants With ACR20 at Week 24 for Treatment Arms That Started Study Intervention From Day 1
Query!
Assessment method [14]
0
0
ACR20 is calculated as a 20% improvement from Baseline in TJC68 and SJC66 and a 20% improvement in 3 of the following 5 measures: Patient's Global Assessment of Arthritis Disease Activity (PtGA), Physician Global Assessment of Arthritis Disease Activity (PhGA) (VAS values from 0=best to 100=worst), Patient Assessment of Arthritis Pain (VAS values from 0=no pain to 100=most severe pain), Health Assessment Questionnaire-Disability Index (HAQ-DI) (0=least difficulty to 3=extreme difficulty) and an acute-phase reactant (high sensitivity C-reactive Protein mg/L (hsCRP).
Query!
Timepoint [14]
0
0
Week 24
Query!
Secondary outcome [15]
0
0
Percentage of Participants With ACR20 at Week 24 for Placebo Switched Arms That Started Study Intervention From Week 12
Query!
Assessment method [15]
0
0
ACR20 is calculated as a 20% improvement from Baseline in TJC68 and SJC66 and a 20% improvement in 3 of the following 5 measures: Patient's Global Assessment of Arthritis Disease Activity (PtGA), Physician Global Assessment of Arthritis Disease Activity (PhGA) (VAS values from 0=best to 100=worst), Patient Assessment of Arthritis Pain (VAS values from 0=no pain to 100=most severe pain), Health Assessment Questionnaire-Disability Index (HAQ-DI) (0=least difficulty to 3=extreme difficulty) and an acute-phase reactant (high sensitivity C-reactive Protein mg/L (hsCRP).
Query!
Timepoint [15]
0
0
Week 24
Query!
Secondary outcome [16]
0
0
Percentage of Participants With 50% Improvement in American College of Rheumatology Criteria (ACR50) at Week 12
Query!
Assessment method [16]
0
0
ACR50 is calculated as a 50% improvement from Baseline in Tender Joint Count 68 (TJC68) and Swollen Joint Count 66 (SJC66) and a 50% improvement in 3 of the following 5 measures: Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale (VAS) with values from 0=best to 100=worst), Physician Global Assessment of Arthritis Disease Activity (PhGA) (VAS with values from 0=best to 100=worst), Patient Assessment of Arthritis Pain (VAS with values from 0=no pain and 100=most severe pain), Health Assessment Questionnaire-Disability Index (HAQ-DI) (ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty) and an acute-phase reactant (high sensitivity C-reactive Protein mg/L (hsCRP)). For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [16]
0
0
Week 12
Query!
Secondary outcome [17]
0
0
Percentage of Participants With ACR50 at Week 24 for Treatment Arms That Started Study Intervention From Day 1
Query!
Assessment method [17]
0
0
ACR50 is calculated as a 50% improvement from Baseline in TJC68 and SJC66 and a 50% improvement in 3 of the following 5 measures: Patient's Global Assessment of Arthritis Disease Activity (PtGA), Physician Global Assessment of Arthritis Disease Activity (PhGA) (VAS values from 0=best to 100=worst), Patient Assessment of Arthritis Pain (VAS values from 0=no pain to 100=most severe pain), Health Assessment Questionnaire-Disability Index (HAQ-DI) (0=least difficulty to 3=extreme difficulty) and an acute-phase reactant (high sensitivity C-reactive Protein mg/L (hsCRP).
Query!
Timepoint [17]
0
0
Week 24
Query!
Secondary outcome [18]
0
0
Percentage of Participants With ACR50 at Week 24 for Placebo Switched Arms That Started Study Intervention From Week 12
Query!
Assessment method [18]
0
0
ACR50 is calculated as a 50% improvement from Baseline in TJC68 and SJC66 and a 50% improvement in 3 of the following 5 measures: Patient's Global Assessment of Arthritis Disease Activity (PtGA), Physician Global Assessment of Arthritis Disease Activity (PhGA) (VAS values from 0=best to 100=worst), Patient Assessment of Arthritis Pain (VAS values from 0=no pain to 100=most severe pain), Health Assessment Questionnaire-Disability Index (HAQ-DI) (0=least difficulty to 3=extreme difficulty) and an acute-phase reactant (high sensitivity C-reactive Protein mg/L (hsCRP).
Query!
Timepoint [18]
0
0
Week 24
Query!
Secondary outcome [19]
0
0
Percentage of Participants With 70% Improvement in American College of Rheumatology Criteria (ACR70) at Week 12
Query!
Assessment method [19]
0
0
ACR70 is calculated as a 70% improvement from Baseline in Tender Joint Count 68 (TJC68) and Swollen Joint Count 66 (SJC66) and a 70% improvement in 3 of the following 5 measures: Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale (VAS) with values from 0=best to 100=worst), Physician Global Assessment of Arthritis Disease Activity (PhGA) (VAS with values from 0=best to 100=worst), Patient Assessment of Arthritis Pain (VAS with values from 0=no pain and 100=most severe pain), Health Assessment Questionnaire-Disability Index (HAQ-DI) (ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty) and an acute-phase reactant (high sensitivity C-reactive Protein mg/L (hsCRP)). For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [19]
0
0
Week 12
Query!
Secondary outcome [20]
0
0
Percentage of Participants With ACR70 at Week 24 for Treatment Arms That Started Study Intervention From Day 1
Query!
Assessment method [20]
0
0
ACR70 is calculated as a 70% improvement from Baseline in TJC68 and SJC66 and a 70% improvement in 3 of the following 5 measures: Patient's Global Assessment of Arthritis Disease Activity (PtGA), Physician Global Assessment of Arthritis Disease Activity (PhGA) (VAS values from 0=best to 100=worst), Patient Assessment of Arthritis Pain (VAS values from 0=no pain to 100=most severe pain), Health Assessment Questionnaire-Disability Index (HAQ-DI) (0=least difficulty to 3=extreme difficulty) and an acute-phase reactant (high sensitivity C-reactive Protein mg/L (hsCRP).
Query!
Timepoint [20]
0
0
Week 24
Query!
Secondary outcome [21]
0
0
Percentage of Participants With ACR70 at Week 24 for Placebo Switched Arms That Started Study Intervention From Week 12
Query!
Assessment method [21]
0
0
ACR70 is calculated as a 70% improvement from Baseline in TJC68 and SJC66 and a 70% improvement in 3 of the following 5 measures: Patient's Global Assessment of Arthritis Disease Activity (PtGA), Physician Global Assessment of Arthritis Disease Activity (PhGA) (VAS values from 0=best to 100=worst), Patient Assessment of Arthritis Pain (VAS values from 0=no pain to 100=most severe pain), Health Assessment Questionnaire-Disability Index (HAQ-DI) (0=least difficulty to 3=extreme difficulty) and an acute-phase reactant (high sensitivity C-reactive Protein mg/L (hsCRP).
Query!
Timepoint [21]
0
0
Week 24
Query!
Secondary outcome [22]
0
0
Percentage of Participants With Disease Activity Score Using 28 Joint Count and C-Reactive Protein (DAS28-CRP) <=3.2 (DAS28-CRP LDA) at Week 12
Query!
Assessment method [22]
0
0
The DAS28-CRP is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), C-reactive protein (CRP) (in mg/L), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28-CRP scores range from 1.0 to 9.4, where lower scores indicates less disease activity. Low disease activity (LDA) is achieved when DAS28-CRP<=3.2. A negative change from baseline in DAS28-CRP indicates an improvement. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [22]
0
0
Week 12
Query!
Secondary outcome [23]
0
0
Percentage of Participants With DAS28-CRP <=3.2 (DAS28-CRP LDA) at Week 24 for Treatment Arms That Started Study Intervention From Day 1
Query!
Assessment method [23]
0
0
The DAS28-CRP is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), C-reactive protein (CRP) (in mg/L), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28-CRP scores range from 1.0 to 9.4, where lower scores indicates less disease activity. Low disease activity (LDA) is achieved when DAS28-CRP<=3.2 . A negative change from baseline in DAS28-CRP indicates an improvement.
Query!
Timepoint [23]
0
0
Week 24
Query!
Secondary outcome [24]
0
0
Percentage of Participants With DAS28-CRP <=3.2 (DAS28-CRP LDA) at Week 24 for Placebo Switched Arms That Started Study Intervention From Week 12
Query!
Assessment method [24]
0
0
The DAS28-CRP is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), C-reactive protein (CRP) (in mg/L), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28-CRP scores range from 1.0 to 9.4, where lower scores indicates less disease activity. Low disease activity (LDA) is achieved when DAS28-CRP<=3.2 . A negative change from baseline in DAS28-CRP indicates an improvement.
Query!
Timepoint [24]
0
0
Week 24
Query!
Secondary outcome [25]
0
0
Percentage of Participants With DAS28 Erythrocyte Sedimentation Rate (ESR) <=3.2 (DAS28-ESR LDA) at Week 12
Query!
Assessment method [25]
0
0
The DAS28-ESR is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), Erythrocyte sedimentation rate (ESR) (in mm/hr), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28-ESR scores range from 1.0 to 9.4, where lower scores indicate less disease activity. Low disease activity (LDA) is achieved when DAS28-ESR<=3.2. A negative change from baseline in DAS28-ESR indicates an improvement. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [25]
0
0
Week 12
Query!
Secondary outcome [26]
0
0
Percentage of Participants With DAS28-ESR <=3.2 (DAS28-ESR LDA) at Week 24 for Treatment Arms That Started Study Intervention From Day 1
Query!
Assessment method [26]
0
0
The DAS28-ESR is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), Erythrocyte sedimentation rate (ESR) (in mm/hr), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28-ESR scores range from 1.0 to 9.4, where lower scores indicate less disease activity. Low disease activity (LDA) is achieved when DAS28-ESR<=3.2. A negative change from baseline in DAS28-ESR indicates an improvement.
Query!
Timepoint [26]
0
0
Week 24
Query!
Secondary outcome [27]
0
0
Percentage of Participants With DAS28-ESR <=3.2 (DAS28-ESR LDA) at Week 24 for Placebo Switched Arms That Started Study Intervention From Week 12
Query!
Assessment method [27]
0
0
The DAS28-ESR is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), Erythrocyte sedimentation rate (ESR) (in mm/hr), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28-ESR scores range from 1.0 to 9.4, where lower scores indicate less disease activity. Low disease activity (LDA) is achieved when DAS28-ESR<=3.2. A negative change from baseline in DAS28-ESR indicates an improvement.
Query!
Timepoint [27]
0
0
Week 24
Query!
Secondary outcome [28]
0
0
Percentage of Participants With DAS28-CRP <2.6 (DAS28-CRP Remission) at Week 12
Query!
Assessment method [28]
0
0
The DAS28-CRP is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), C-reactive protein (CRP) (in mg/L), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28-CRP scores range from 1.0 to 9.4, where lower scores indicates less disease activity. Remission is achieved when DAS28-CRP <2.6. A negative change from baseline in DAS28-CRP indicates an improvement. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [28]
0
0
Week 12
Query!
Secondary outcome [29]
0
0
Percentage of Participants With DAS28-CRP <2.6 (DAS28-CRP Remission) at Week 24 for Treatment Arms That Started Study Intervention From Day 1
Query!
Assessment method [29]
0
0
The DAS28-CRP arthritis is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), C-reactive protein (CRP) (in mg/L), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28-CRP scores range from 1.0 to 9.4, where lower scores indicates less disease activity. Remission is achieved when DAS28-CRP <2.6. A negative change from baseline in DAS28-CRP indicates an improvement.
Query!
Timepoint [29]
0
0
Week 24
Query!
Secondary outcome [30]
0
0
Percentage of Participants With DAS28-CRP <2.6 (DAS28-CRP Remission) at Week 24 for Placebo Switched Arms That Started Study Intervention From Week 12
Query!
Assessment method [30]
0
0
The DAS28-CRP arthritis is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), C-reactive protein (CRP) (in mg/L), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28-CRP scores range from 1.0 to 9.4, where lower scores indicates less disease activity. Remission is achieved when DAS28-CRP <2.6. A negative change from baseline in DAS28-CRP indicates an improvement.
Query!
Timepoint [30]
0
0
Week 24
Query!
Secondary outcome [31]
0
0
Percentage of Participants With DAS28-ESR <2.6 (DAS28-ESR Remission) at Week 12
Query!
Assessment method [31]
0
0
The DAS28-ESR is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), Erythrocyte sedimentation rate (ESR) (in mm/hr), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28-ESR scores range from 1.0 to 9.4, where lower scores indicates less disease activity. Remission is achieved when DAS28-ESR <2.6. A negative change from baseline in DAS28-ESR indicates an improvement. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [31]
0
0
Week 12
Query!
Secondary outcome [32]
0
0
Percentage of Participants With DAS28-ESR <2.6 (DAS28-ESR Remission) Week 24 for Treatment Arms That Started Study Intervention From Day 1
Query!
Assessment method [32]
0
0
The DAS28-ESR is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), Erythrocyte sedimentation rate (ESR) (in mm/hr), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28-ESR scores range from 1.0 to 9.4, where lower scores indicates less disease activity. Remission is achieved when DAS28-ESR <2.6. A negative change from baseline in DAS28-ESR indicates an improvement.
Query!
Timepoint [32]
0
0
Week 24
Query!
Secondary outcome [33]
0
0
Percentage of Participants With DAS28-ESR <2.6 (DAS28-ESR Remission) Week 24 for Placebo Switched Arms That Started Study Intervention From Week 12
Query!
Assessment method [33]
0
0
The DAS28-ESR is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), Erythrocyte sedimentation rate (ESR) (in mm/hr), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28-ESR scores range from 1.0 to 9.4, where lower scores indicates less disease activity. Remission is achieved when DAS28-ESR <2.6. A negative change from baseline in DAS28-ESR indicates an improvement.
Query!
Timepoint [33]
0
0
Week 24
Query!
Secondary outcome [34]
0
0
Percentage of Participants With a Good/Moderate European League Against Rheumatism (EULAR) Response at Week 12
Query!
Assessment method [34]
0
0
DAS28-CRP and DAS28-ESR scores categorized using EULAR response criteria. Response based on the combination of current DAS28 score and the improvement in the current DAS28 score relative to baseline (Good response = DAS28 change >1.2 with current DAS28 =3.2; Moderate response = DAS28 change >0.6 with current DAS28 >3.2-5.1; Non-response = DAS28 change =0.6 and current DAS28 >5.1). For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [34]
0
0
Week 12
Query!
Secondary outcome [35]
0
0
Percentage of Participants With a Good/Moderate EULAR Response at Week 24 for Treatment Arms That Started Study Intervention From Day 1
Query!
Assessment method [35]
0
0
DAS28-CRP and DAS28-ESR scores categorised using EULAR response criteria. Response based on the combination of current DAS28 score and the improvement in the current DAS28 score relative to baseline (Good response = DAS28 change >1.2 with current DAS28 =3.2; Moderate response = DAS28 change >0.6 with current DAS28 >3.2-5.1; Non-response = DAS28 change =0.6 and current DAS28 >5.1).
Query!
Timepoint [35]
0
0
Week 24
Query!
Secondary outcome [36]
0
0
Percentage of Participants With a Good/Moderate EULAR Response at Week 24 for Placebo Switched Arms That Started Study Intervention From Week 12
Query!
Assessment method [36]
0
0
DAS28-CRP and DAS28-ESR scores categorised using EULAR response criteria. Response based on the combination of current DAS28 score and the improvement in the current DAS28 score relative to baseline (Good response = DAS28 change >1.2 with current DAS28 =3.2; Moderate response = DAS28 change >0.6 with current DAS28 >3.2-5.1; Non-response = DAS28 change =0.6 and current DAS28 >5.1).
Query!
Timepoint [36]
0
0
Week 24
Query!
Secondary outcome [37]
0
0
Percentage of Participants With ACR/EULAR Remission at Week 12
Query!
Assessment method [37]
0
0
Boolean-based ACR/EULAR remission is achieved if all of the following requirements are met at the same timepoint: Tender Joint Count 68 (TJC68) = 1, Swollen Joint Count 66 (SJC66) = 1, high sensitivity C-reactive Protein (hsCRP) = 1mg/dl and patient's global assessment of disease activity (PtGA) = 10. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [37]
0
0
Week 12
Query!
Secondary outcome [38]
0
0
Percentage of Participants With ACR/EULAR Remission at Week 24 for Treatment Arms That Started Study Intervention From Day 1
Query!
Assessment method [38]
0
0
Boolean-based ACR/EULAR remission is achieved if all of the following requirements are met at the same timepoint: Tender Joint Count 68 (TJC68) = 1, Swollen Joint Count 66 (SJC66) = 1, high sensitivity C-reactive Protein (CRP) = 1mg/dl and patient's global assessment of disease activity (PtGA) = 10.
Query!
Timepoint [38]
0
0
Week 24
Query!
Secondary outcome [39]
0
0
Percentage of Participants With ACR/EULAR Remission at Week 24 for Placebo Switched Arms That Started Study Intervention From Week 12
Query!
Assessment method [39]
0
0
Boolean-based ACR/EULAR remission is achieved if all of the following requirements are met at the same timepoint: Tender Joint Count 68 (TJC68) = 1, Swollen Joint Count 66 (SJC66) = 1, high sensitivity C-reactive Protein (CRP) = 1mg/dl and patient's global assessment of disease activity (PtGA) = 10.
Query!
Timepoint [39]
0
0
Week 24
Query!
Secondary outcome [40]
0
0
Change From Baseline in DAS28-CRP and DAS28-ESR at Week 12
Query!
Assessment method [40]
0
0
DAS28-CRP and DAS28-ESR are measure of RA disease activity calculated using Swollen Joint Count 28 (TJC28), Tender Joint Count 28 (TJC28), high sensitivity C-reactive Protein (hsCRP in mg/L)/Erythrocyte sedimentation rate (ESR in mm/hr (mm/hour) and patient's global assessment of disease activity (PtGA) transformed to a 0-10 scale. Total score approximate range 0-9.4, with higher scores indicating more disease activity. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [40]
0
0
Baseline (Day 01) and Week 12
Query!
Secondary outcome [41]
0
0
Change From Baseline in DAS28-CRP and DAS28-ESR at Week 24 for Treatment Arms That Started Study Intervention From Day 1
Query!
Assessment method [41]
0
0
DAS28-CRP and DAS28-ESR are measure of RA disease activity calculated using Swollen Joint Count 28 (TJC28), Tender Joint Count 28 (TJC28), high sensitivity C-reactive Protein (hsCRP in mg/L)/Erythrocyte sedimentation rate (ESR in mm/hr (mm/hour) and patient's global assessment of disease activity (PtGA) transformed to a 0-10 scale. Total score approximate range 0-9.4, with higher scores indicating more disease activity.
Query!
Timepoint [41]
0
0
Baseline (Day 01) and Week 24
Query!
Secondary outcome [42]
0
0
Change From Baseline in DAS28-CRP and DAS28-ESR at Week 24 for Placebo Switched Arms That Started Study Intervention From Week 12
Query!
Assessment method [42]
0
0
DAS28-CRP and DAS28-ESR are measure of RA disease activity calculated using Swollen Joint Count 28 (TJC28), Tender Joint Count 28 (TJC28), high sensitivity C-reactive Protein (hsCRP in mg/L)/Erythrocyte sedimentation rate (ESR in mm/hr (mm/hour) and patient's global assessment of disease activity (PtGA) transformed to a 0-10 scale. Total score approximate range 0-9.4, with higher scores indicating more disease activity.
Query!
Timepoint [42]
0
0
Baseline (Day 01) and Week 24
Query!
Secondary outcome [43]
0
0
Change From Baseline in HAQ-DI at Week 24 for Treatment Arms That Started Study Intervention From Day 1
Query!
Assessment method [43]
0
0
Health Assessment Questionnaire-Disability Index (HAQ-DI) is a 20-question instrument that assesses the difficulty of a participant in eight domains of daily activities: Dressing & grooming, Arising, Eating, Walking, Hygiene, Reach, Grip, Common daily activities. HAQ-DI score was computed as sum of the domain scores divided by the number of domains answered. The total possible score ranges from 0=least difficulty to 3=extreme difficulty. Higher overall score indicates greater disability. A negative change from baseline indicates an improvement.
Query!
Timepoint [43]
0
0
Baseline (Day 01) and Week 24
Query!
Secondary outcome [44]
0
0
Change From Baseline in HAQ-DI at Week 24 for Placebo Switched Arms That Started Study Intervention From Week 12
Query!
Assessment method [44]
0
0
Health Assessment Questionnaire-Disability Index (HAQ-DI) is a 20-question instrument that assesses the difficulty of a participant in eight domains of daily activities: Dressing & grooming, Arising, Eating, Walking, Hygiene, Reach, Grip, Common daily activities. HAQ-DI score was computed as sum of the domain scores divided by the number of domains answered. The total possible score ranges from 0=least difficulty to 3=extreme difficulty. Higher overall score indicates greater disability. A negative change from baseline indicates an improvement.
Query!
Timepoint [44]
0
0
Baseline (Day 01) and Week 24
Query!
Secondary outcome [45]
0
0
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue at Week 12
Query!
Assessment method [45]
0
0
The Functional Assessment of Chronic Illness Therapy (FACIT)-fatigue is a validated patient-reported measure of 13 statements regarding the feeling of fatigue. The total score ranges from 0 to 52 with higher values representing a lower fatigue and a better quality of life. A positive change from baseline in FACIT-fatigue indicates an improvement. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [45]
0
0
Baseline (Day 01) and Week 12
Query!
Secondary outcome [46]
0
0
Change From Baseline in FACIT-Fatigue at Week 24 for Treatment Arms That Started Study Intervention From Day 1
Query!
Assessment method [46]
0
0
The Functional Assessment of Chronic Illness Therapy (FACIT)-fatigue is a validated patient-reported measure of 13 statements regarding the feeling of fatigue. The total score ranges from 0 to 52 with higher values representing a lower fatigue and a better quality of life. A positive change from baseline in FACIT-fatigue indicates an improvement.
Query!
Timepoint [46]
0
0
Baseline (Day 01) and Week 24
Query!
Secondary outcome [47]
0
0
Change From Baseline in FACIT-Fatigue at Week 24 for Placebo Switched Arms That Started Study Intervention From Week 12
Query!
Assessment method [47]
0
0
The Functional Assessment of Chronic Illness Therapy (FACIT)-fatigue is a validated patient-reported measure of 13 statements regarding the feeling of fatigue. The total score ranges from 0 to 52 with higher values representing a lower fatigue and a better quality of life. A positive change from baseline in FACIT-fatigue indicates an improvement.
Query!
Timepoint [47]
0
0
Baseline (Day 01) and Week 24
Query!
Secondary outcome [48]
0
0
Change From Baseline in Subject-completed Medical Outcomes Study Short-Form 36 (SF-36) Physical Component Scores (PCS) at Week 12
Query!
Assessment method [48]
0
0
The Short-Form 36 (SF-36) is a health-related survey that assesses quality of life covering 8 domains: physical functioning, bodily pain, role limitations due to physical and emotional problems, general health, mental health, social functioning, vitality. The score for a domain was an average of the individual question scores, which were scaled 0-100; higher score represents better health. The PCS is an aggregate score derived from 4 domains (physical functioning, role-physical, bodily pain and general health) representing overall physical health. T-score scale was used for PCS with mean of 50 and SD of 10; higher score represents better health. A positive change from baseline indicates an improvement in overall physical heath. Quality Metrics software was used for scoring for SF-36. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [48]
0
0
Baseline (Day 01) and Week 12
Query!
Secondary outcome [49]
0
0
Change From Baseline in SF-36 PCS at Week 24 for Treatment Arms That Started Study Intervention From Day 1
Query!
Assessment method [49]
0
0
The Short-Form 36 (SF-36) is a health-related survey that assesses quality of life covering 8 domains: physical functioning, bodily pain, role limitations due to physical and emotional problems, general health, mental health, social functioning, vitality. The score for a domain was an average of the individual question scores, which were scaled 0-100; higher score represents better health. The PCS is an aggregate score derived from 4 domains (physical functioning, role-physical, bodily pain and general health) representing overall physical health. T-score scale was used for PCS with mean of 50 and SD of 10; higher score represents better health. A positive change from baseline indicates an improvement in overall physical heath. Quality Metrics software was used for scoring for SF-36.
Query!
Timepoint [49]
0
0
Baseline (Day 01) and Week 24
Query!
Secondary outcome [50]
0
0
Change From Baseline in SF-36 PCS at Week 24 for Placebo Switched Arms That Started Study Intervention From Week 12
Query!
Assessment method [50]
0
0
The Short-Form 36 (SF-36) is a health-related survey that assesses quality of life covering 8 domains: physical functioning, bodily pain, role limitations due to physical and emotional problems, general health, mental health, social functioning, vitality. The score for a domain was an average of the individual question scores, which were scaled 0-100; higher score represents better health. The PCS is an aggregate score derived from 4 domains (physical functioning, role-physical, bodily pain and general health) representing overall physical health. T-score scale was used for PCS with mean of 50 and SD of 10; higher score represents better health. A positive change from baseline indicates an improvement in overall physical heath. Quality Metrics software was used for scoring for SF-36.
Query!
Timepoint [50]
0
0
Baseline (Day 01) and Week 24
Query!
Secondary outcome [51]
0
0
Change From Baseline in SF-36 Mental Component Scores (MCS) at Week 12
Query!
Assessment method [51]
0
0
The Short-Form 36 (SF-36) is a health-related survey that assesses quality of life covering 8 domains: physical functioning, bodily pain, role limitations due to physical and emotional problems, general health, mental health, social functioning, vitality. The score for a domain was an average of the individual question scores, which were scaled 0-100; higher score represents better health. The MCS is an aggregated score derived from 4 domains (social functioning, vitality, mental health, and role-emotional domains) representing overall mental health. T-score scale was used for MCS with mean of 50 and SD of 10; higher score represents better health. A positive change from baseline indicates an improvement in overall mental health. Quality Metrics software was used for scoring for SF-36. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [51]
0
0
Baseline (Day 01) and Week 12
Query!
Secondary outcome [52]
0
0
Change From Baseline in SF-36 MCS at Week 24 for Treatment Arms That Started Study Intervention From Day 1
Query!
Assessment method [52]
0
0
The Short-Form 36 (SF-36) is a health-related survey that assesses quality of life covering 8 domains: physical functioning, bodily pain, role limitations due to physical and emotional problems, general health, mental health, social functioning, vitality. The score for a domain was an average of the individual question scores, which were scaled 0-100; higher score represents better health. The MCS is an aggregated score derived from 4 domains (social functioning, vitality, mental health, and role-emotional domains) representing overall mental health. T-score scale was used for MCS with mean of 50 and SD of 10; higher score represents better health. A positive change from baseline indicates an improvement in overall mental health. Quality Metrics software was used for scoring for SF-36.
Query!
Timepoint [52]
0
0
Baseline (Day 01) and Week 24
Query!
Secondary outcome [53]
0
0
Change From Baseline in SF-36 MCS at Week 24 for Placebo Switched Arms That Started Study Intervention From Week 12
Query!
Assessment method [53]
0
0
The Short-Form 36 (SF-36) is a health-related survey that assesses quality of life covering 8 domains: physical functioning, bodily pain, role limitations due to physical and emotional problems, general health, mental health, social functioning, vitality. The score for a domain was an average of the individual question scores, which were scaled 0-100; higher score represents better health. The MCS is an aggregated score derived from 4 domains (social functioning, vitality, mental health, and role-emotional domains) representing overall mental health. T-score scale was used for MCS with mean of 50 and SD of 10; higher score represents better health. A positive change from baseline indicates an improvement in overall mental health. Quality Metrics software was used for scoring for SF-36.
Query!
Timepoint [53]
0
0
Baseline (Day 01) and Week 24
Query!
Secondary outcome [54]
0
0
Change From Baseline in SF-36 Domain Scores at Week 12
Query!
Assessment method [54]
0
0
The Short-Form 36 (SF-36) is a health-related survey that assesses quality of life covering 8 domains: physical functioning, bodily pain, role limitations due to physical and emotional problems, general health, mental health, social functioning, vitality. The MCS consists of 4 domains (social functioning, vitality, mental health, and role-emotional domains) and PCS consists of 4 domains (physical functioning, role-physical, bodily pain and general health). The individual question items are first summed for each item under the various sections. Then, those domain scores are scaled between 0 to 100, where higher score represents better health. A positive change from baseline indicates an improvement. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [54]
0
0
Baseline (Day 01) and Week 12
Query!
Secondary outcome [55]
0
0
Change From Baseline in SF-36 Domain Scores at Week 24 for Treatment Arms That Started Study Intervention From Day 1
Query!
Assessment method [55]
0
0
The Short-Form 36 (SF-36) is a health-related survey that assesses quality of life covering 8 domains: physical functioning, bodily pain, role limitations due to physical and emotional problems, general health, mental health, social functioning, vitality. The MCS consists of 4 domains (social functioning, vitality, mental health, and role-emotional domains) and PCS consists of 4 domains (physical functioning, role-physical, bodily pain and general health). The individual question items are first summed for each item under the various sections. Then, those domain scores are scaled between 0 to 100, where higher score represents better health. A positive change from baseline indicates an improvement.
Query!
Timepoint [55]
0
0
Baseline (Day 01) and Week 24
Query!
Secondary outcome [56]
0
0
Change From Baseline in SF-36 Domain Scores at Week 24 for Placebo Switched Arms That Started Study Intervention From Week 12
Query!
Assessment method [56]
0
0
The Short-Form 36 (SF-36) is a health-related survey that assesses quality of life covering 8 domains: physical functioning, bodily pain, role limitations due to physical and emotional problems, general health, mental health, social functioning, vitality. The MCS consists of 4 domains (social functioning, vitality, mental health, and role-emotional domains) and PCS consists of 4 domains (physical functioning, role-physical, bodily pain and general health). The individual question items are first summed for each item under the various sections. Then, those domain scores are scaled between 0 to 100, where higher score represents better health. A positive change from baseline indicates an improvement.
Query!
Timepoint [56]
0
0
Baseline (Day 01) and Week 24
Query!
Secondary outcome [57]
0
0
Incidence of Adverse Events (AEs), Serious Adverse Event (SAEs), Adverse Events of Special Interest (AESI)
Query!
Assessment method [57]
0
0
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A SAE is any untoward medical occurrence that, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity and/or can result in death.
Query!
Timepoint [57]
0
0
Up to Week 24
Query!
Secondary outcome [58]
0
0
Change From Baseline in Neutrophil, Lymphocyte, Platelet Count (Giga Cells Per Liter) at Week 12
Query!
Assessment method [58]
0
0
Blood samples was collected for the assessment of change from baseline in hematology parameters including neutrophil, lymphocyte, platelet count. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [58]
0
0
Baseline (Day 01) and Week 12
Query!
Secondary outcome [59]
0
0
Change From Baseline in Neutrophil, Lymphocyte, Platelet Count (Giga Cells Per Liter) at Week 24 for Treatment Arms That Started Study Intervention From Day 1
Query!
Assessment method [59]
0
0
Blood samples was collected for the assessment of change from baseline in hematology parameters including neutrophil, lymphocyte, platelet count.
Query!
Timepoint [59]
0
0
Baseline (Day 01) and Week 24
Query!
Secondary outcome [60]
0
0
Change From Baseline in Neutrophil, Lymphocyte, Platelet Count (Giga Cells Per Liter) at Week 24 for Placebo Switched Arms That Started Study Intervention From Week 12
Query!
Assessment method [60]
0
0
Blood samples was collected for the assessment of change from baseline in hematology parameters including neutrophil, lymphocyte, platelet count.
Query!
Timepoint [60]
0
0
Baseline (Week 12) and Week 24
Query!
Secondary outcome [61]
0
0
Change From Baseline in White Blood Cell (WBC) Count (Giga Cells Per Liter) at Week 12
Query!
Assessment method [61]
0
0
Blood samples was collected for the assessment of change from baseline in hematology parameter WBC count. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [61]
0
0
Baseline (Day 01) and Week 12
Query!
Secondary outcome [62]
0
0
Change From Baseline in WBC Count (Giga Cells Per Liter) at Week 24 for Treatment Arms That Started Study Intervention From Day 1
Query!
Assessment method [62]
0
0
Blood samples was collected for the assessment of change from baseline in hematology parameter WBC count.
Query!
Timepoint [62]
0
0
Baseline (Day 01) and Week 24
Query!
Secondary outcome [63]
0
0
Change From Baseline in WBC Count (Giga Cells Per Liter) at Week 24 for Placebo Switched Arms That Started Study Intervention From Week 12
Query!
Assessment method [63]
0
0
Blood samples was collected for the assessment of change from baseline in hematology parameter WBC count.
Query!
Timepoint [63]
0
0
Baseline (Week 12) and Week 24
Query!
Secondary outcome [64]
0
0
Change From Baseline in Hemoglobin Level (Grams Per Liter) Week 12
Query!
Assessment method [64]
0
0
Blood samples was collected for the assessment of change from baseline in hematology parameter hemoglobin level. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [64]
0
0
Baseline (Day 01) and Week 12
Query!
Secondary outcome [65]
0
0
Change From Baseline in Hemoglobin Level (Grams Per Liter) Week 24 for Treatment Arms That Started Study Intervention From Day 1
Query!
Assessment method [65]
0
0
Blood samples was collected for the assessment of change from baseline in in hematology parameter hemoglobin level.
Query!
Timepoint [65]
0
0
Baseline (Day 01) and Week 24
Query!
Secondary outcome [66]
0
0
Change From Baseline in Hemoglobin Level (Grams Per Liter) Week 24 for Placebo Switched Arms That Started Study Intervention From Week 12
Query!
Assessment method [66]
0
0
Blood samples was collected for the assessment of change from baseline in in hematology parameter hemoglobin level.
Query!
Timepoint [66]
0
0
Baseline (Week 12) and Week 24
Query!
Secondary outcome [67]
0
0
Change From Baseline in Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP) Gamma-glutamyl Transferase(GGT) Levels (International Units Per Liter) at Week 12
Query!
Assessment method [67]
0
0
Blood samples was collected for the assessment of change from baseline in laboratory parameters including aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (AP) gamma-glutamyl transferase (GGT) levels. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [67]
0
0
Baseline (Day 01) and Week 12
Query!
Secondary outcome [68]
0
0
Change From Baseline in AST, ALT, AP, GGT Levels (International Units Per Liter) at Week 24 for Treatment Arms That Started Study Intervention From Day 1
Query!
Assessment method [68]
0
0
Blood samples was collected for the assessment of change from baseline in laboratory parameters including AST, ALT, AP, GGT levels.
Query!
Timepoint [68]
0
0
Baseline (Day 01) and Week 24
Query!
Secondary outcome [69]
0
0
Change From Baseline in AST, ALT, AP, GGT Levels (International Units Per Liter) at Week 24 for Placebo Switched Arms That Started Study Intervention From Week 12
Query!
Assessment method [69]
0
0
Blood samples was collected for the assessment of change from baseline in laboratory parameters including AST, ALT, AP, GGT levels.
Query!
Timepoint [69]
0
0
Baseline (Week 12) and Week 24
Query!
Secondary outcome [70]
0
0
Change From Baseline in Albumin Level (Grams Per Liter) at Week 12
Query!
Assessment method [70]
0
0
Blood samples was collected for the assessment of change from baseline in laboratory parameter albumin level. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [70]
0
0
Baseline (Day 01) and Week 12
Query!
Secondary outcome [71]
0
0
Change From Baseline in Albumin Level (Grams Per Liter) at Week 24 for Treatment Arms That Started Study Intervention From Day 1
Query!
Assessment method [71]
0
0
Blood samples was collected for the assessment of change from baseline in laboratory parameter albumin level.
Query!
Timepoint [71]
0
0
Baseline (Day 01) and Week 24
Query!
Secondary outcome [72]
0
0
Change From Baseline in Albumin Level (Grams Per Liter) at Week 24 for Placebo Switched Arms That Started Study Intervention From Week 12
Query!
Assessment method [72]
0
0
Blood samples was collected for the assessment of change from baseline in laboratory parameter albumin level.
Query!
Timepoint [72]
0
0
Baseline (Week 12) and Week 24
Query!
Secondary outcome [73]
0
0
Change From Baseline in Total Bilirubin (Micromoles Per Liter) at Week 12
Query!
Assessment method [73]
0
0
Blood samples was collected for the assessment of change from baseline in laboratory parameter total bilirubin level. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [73]
0
0
Baseline (Day 01) and Week 12
Query!
Secondary outcome [74]
0
0
Change From Baseline in Total Bilirubin (Micromoles Per Liter) at Week 24 for Treatment Arms That Started Study Intervention From Day 1
Query!
Assessment method [74]
0
0
Blood samples was collected for the assessment of change from baseline in laboratory parameter bilirubin level.
Query!
Timepoint [74]
0
0
Baseline (Day 01) and Week 24
Query!
Secondary outcome [75]
0
0
Change From Baseline in Total Bilirubin (Micromoles Per Liter) at Week 24 for Placebo Switched Arms That Started Study Intervention From Week 12
Query!
Assessment method [75]
0
0
Blood samples was collected for the assessment of change from baseline in laboratory parameter bilirubin level.
Query!
Timepoint [75]
0
0
Baseline (Week 12) and Week 24
Query!
Secondary outcome [76]
0
0
Change From Baseline in Total Cholesterol (Millimoles Per Liter) at Week 12
Query!
Assessment method [76]
0
0
Blood samples was collected for the assessment of change from baseline in lipid profile of total cholesterol levels. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [76]
0
0
Baseline (Day 01) and Week 12
Query!
Secondary outcome [77]
0
0
Change From Baseline in Total Cholesterol (Millimoles Per Liter) at Week 24 for Treatment Arms That Started Study Intervention From Day 1
Query!
Assessment method [77]
0
0
Blood samples was collected for the assessment of change from baseline in lipid profile of total cholesterol levels.
Query!
Timepoint [77]
0
0
Baseline (Day 01) and Week 24
Query!
Secondary outcome [78]
0
0
Change From Baseline in Total Cholesterol (Millimoles Per Liter) at Week 24 for Placebo Switched Arms That Started Study Intervention From Week 12
Query!
Assessment method [78]
0
0
Blood samples was collected for the assessment of change from baseline in lipid profile of total cholesterol levels.
Query!
Timepoint [78]
0
0
Baseline (Week 12) and Week 24
Query!
Secondary outcome [79]
0
0
Change From Baseline in Fasting Lipid Profile: Low-density Lipoprotein (LDL) Cholesterol, High-density Lipoprotein (HDL) Cholesterol (Millimoles Per Liter) at Week 12
Query!
Assessment method [79]
0
0
Blood samples was collected for the assessment of change from baseline in fasting lipid profile including LDL cholesterol, HDL cholesterol levels. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [79]
0
0
Baseline (Day 01) and Week 12
Query!
Secondary outcome [80]
0
0
Change From Baseline in Fasting Lipid Profile: LDL Cholesterol, HDL Cholesterol (Millimoles Per Liter) at Week 24 for Treatment Arms That Started Study Intervention From Day 1
Query!
Assessment method [80]
0
0
Blood samples was collected for the assessment of change from baseline in fasting lipid profile including LDL cholesterol, HDL cholesterol levels.
Query!
Timepoint [80]
0
0
Baseline (Day 01) and Week 24
Query!
Secondary outcome [81]
0
0
Change From Baseline in Fasting Lipid Profile: LDL Cholesterol, HDL Cholesterol (Millimoles Per Liter) at Week 24 for Placebo Switched Arms That Started Study Intervention From Week 12
Query!
Assessment method [81]
0
0
Blood samples was collected for the assessment of change from baseline in fasting lipid profile including LDL cholesterol, HDL cholesterol levels.
Query!
Timepoint [81]
0
0
Baseline (Week 12) and Week 24
Query!
Secondary outcome [82]
0
0
Change From Baseline in Fasting Lipid Profile Triglycerides (Millimoles Per Liter) at Week 12
Query!
Assessment method [82]
0
0
Blood samples was collected for the assessment of change from baseline in fasting lipid profile triglycerides levels. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [82]
0
0
Baseline (Day 01) and Week 12
Query!
Secondary outcome [83]
0
0
Change From Baseline in Fasting Lipid Profile Triglycerides (Millimoles Per Liter) at Week 24 for Treatment Arms That Started Study Intervention From Day 1
Query!
Assessment method [83]
0
0
Blood samples was collected for the assessment of change from baseline in fasting lipid profile triglycerides levels.
Query!
Timepoint [83]
0
0
Baseline (Day 01) and Week 24
Query!
Secondary outcome [84]
0
0
Change From Baseline in Fasting Lipid Profile Triglycerides (Millimoles Per Liter) at Week 24 for Placebo Switched Arms That Started Study Intervention From Week 12
Query!
Assessment method [84]
0
0
Blood samples was collected for the assessment of change from baseline in fasting lipid profile triglycerides levels.
Query!
Timepoint [84]
0
0
Baseline (Week 12) and Week 24
Query!
Secondary outcome [85]
0
0
Number of Participants With National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) >=Grade 3 Hematological/Clinical Chemistry Abnormalities for Treatment Arms That Started Study Intervention From Day 1
Query!
Assessment method [85]
0
0
Number of participants who reported NCI-CTCAE Grade 3 or higher for hematological and clinical chemistry abnormalities were summarized.
Query!
Timepoint [85]
0
0
Up to Week 24
Query!
Secondary outcome [86]
0
0
Concentrations of Granulocyte-macrophage Colony Stimulating Factor (GM-CSF) Autoantibody
Query!
Assessment method [86]
0
0
Blood samples were collected for markers which may influence rheumatoid arthritis. Concentrations of GM-CSF autoantibodies was determined.
Query!
Timepoint [86]
0
0
At baseline
Query!
Secondary outcome [87]
0
0
Number of Participants With Anti-GSK3196165 Antibodies
Query!
Assessment method [87]
0
0
Blood samples were collected for anti-GSK3196165 antibodies detection assay using tiered testing schema: screening, confirmation and titration steps was used for immunogenicity analysis.
Query!
Timepoint [87]
0
0
Up to Week 24
Query!
Eligibility
Key inclusion criteria
Key inclusion criteria:
- >=18 years of age
- Has had RA for >=6 months and was not diagnosed before 16 years of age
- Has active disease, as defined by having both:*
- >=6/68 tender/painful joints (tender joint count [TJC]), and
- >=6/66 swollen joints (swollen joint count [SJC])
- Has had an inadequate response despite currently taking at least one and at the most
two concomitant csDMARDs for at least 12 weeks, from the following:
- Methotrexate (MTX)
- Hydroxychloroquine or chloroquine
- Sulfasalazine
- Leflunomide
- Bucillamine
- Iguratimod
- Tacrolimus
- Has had inadequate response to at least one bDMARD at an approved dose and/or at least
one JAK inhibitors at an approved dose. In both cases this may be with or without
combination with a csDMARD.
- If surgical treatment of a joint has been performed, that joint cannot be counted
in the TJC or SJC.
Key exclusion criteria:
- Has had any active and/or recurrent infections (excluding recurrent fungal infections
of the nail bed) or has required management of acute or chronic infections.
- Has received prior treatment with an antagonist of GM-CSF or its receptor.
- Has known infection with human immunodeficiency virus (HIV) or current acute or
chronic hepatitis B and/or hepatitis C.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
31/10/2019
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/02/2022
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
550
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Illinois
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Missouri
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Nebraska
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
New Hampshire
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
North Dakota
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Ohio
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Oklahoma
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
South Carolina
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Texas
Query!
Country [14]
0
0
Argentina
Query!
State/province [14]
0
0
Buenos Aires
Query!
Country [15]
0
0
Argentina
Query!
State/province [15]
0
0
Ciudad Autónoma de Buenos Aires
Query!
Country [16]
0
0
Argentina
Query!
State/province [16]
0
0
San Juan
Query!
Country [17]
0
0
Belgium
Query!
State/province [17]
0
0
Mons
Query!
Country [18]
0
0
Canada
Query!
State/province [18]
0
0
Ontario
Query!
Country [19]
0
0
Canada
Query!
State/province [19]
0
0
Quebec
Query!
Country [20]
0
0
Czechia
Query!
State/province [20]
0
0
Brno
Query!
Country [21]
0
0
Czechia
Query!
State/province [21]
0
0
Ostrava
Query!
Country [22]
0
0
Czechia
Query!
State/province [22]
0
0
Praha 11
Query!
Country [23]
0
0
Czechia
Query!
State/province [23]
0
0
Praha 2
Query!
Country [24]
0
0
Czechia
Query!
State/province [24]
0
0
Praha 5
Query!
Country [25]
0
0
Czechia
Query!
State/province [25]
0
0
Uherske Hradiste
Query!
Country [26]
0
0
Czechia
Query!
State/province [26]
0
0
Zlin
Query!
Country [27]
0
0
Germany
Query!
State/province [27]
0
0
Schleswig-Holstein
Query!
Country [28]
0
0
Germany
Query!
State/province [28]
0
0
Hamburg
Query!
Country [29]
0
0
Germany
Query!
State/province [29]
0
0
Magdeburg
Query!
Country [30]
0
0
Hungary
Query!
State/province [30]
0
0
Budapest
Query!
Country [31]
0
0
Hungary
Query!
State/province [31]
0
0
Szekesfehervar
Query!
Country [32]
0
0
Hungary
Query!
State/province [32]
0
0
Veszprem
Query!
Country [33]
0
0
Italy
Query!
State/province [33]
0
0
Veneto
Query!
Country [34]
0
0
Japan
Query!
State/province [34]
0
0
Aichi
Query!
Country [35]
0
0
Japan
Query!
State/province [35]
0
0
Chiba
Query!
Country [36]
0
0
Japan
Query!
State/province [36]
0
0
Fukuoka
Query!
Country [37]
0
0
Japan
Query!
State/province [37]
0
0
Hokkaido
Query!
Country [38]
0
0
Japan
Query!
State/province [38]
0
0
Hyogo
Query!
Country [39]
0
0
Japan
Query!
State/province [39]
0
0
Ibaraki
Query!
Country [40]
0
0
Japan
Query!
State/province [40]
0
0
Kagoshima
Query!
Country [41]
0
0
Japan
Query!
State/province [41]
0
0
Kanagawa
Query!
Country [42]
0
0
Japan
Query!
State/province [42]
0
0
Kochi
Query!
Country [43]
0
0
Japan
Query!
State/province [43]
0
0
Kumamoto
Query!
Country [44]
0
0
Japan
Query!
State/province [44]
0
0
Miyagi
Query!
Country [45]
0
0
Japan
Query!
State/province [45]
0
0
Nagasaki
Query!
Country [46]
0
0
Japan
Query!
State/province [46]
0
0
Saitama
Query!
Country [47]
0
0
Japan
Query!
State/province [47]
0
0
Tokyo
Query!
Country [48]
0
0
Korea, Republic of
Query!
State/province [48]
0
0
Incheon
Query!
Country [49]
0
0
Korea, Republic of
Query!
State/province [49]
0
0
Seoul
Query!
Country [50]
0
0
Lithuania
Query!
State/province [50]
0
0
Klaipeda
Query!
Country [51]
0
0
Lithuania
Query!
State/province [51]
0
0
Siauliai
Query!
Country [52]
0
0
Poland
Query!
State/province [52]
0
0
Bialystok
Query!
Country [53]
0
0
Poland
Query!
State/province [53]
0
0
Bydgoszcz
Query!
Country [54]
0
0
Poland
Query!
State/province [54]
0
0
Gdansk
Query!
Country [55]
0
0
Poland
Query!
State/province [55]
0
0
Gdynia
Query!
Country [56]
0
0
Poland
Query!
State/province [56]
0
0
Katowice
Query!
Country [57]
0
0
Poland
Query!
State/province [57]
0
0
Kraków
Query!
Country [58]
0
0
Poland
Query!
State/province [58]
0
0
Lodz
Query!
Country [59]
0
0
Poland
Query!
State/province [59]
0
0
Poznan
Query!
Country [60]
0
0
Poland
Query!
State/province [60]
0
0
Sochaczew
Query!
Country [61]
0
0
Poland
Query!
State/province [61]
0
0
Torun
Query!
Country [62]
0
0
Poland
Query!
State/province [62]
0
0
Warszawa
Query!
Country [63]
0
0
Poland
Query!
State/province [63]
0
0
Wroclaw
Query!
Country [64]
0
0
South Africa
Query!
State/province [64]
0
0
Gauteng
Query!
Country [65]
0
0
South Africa
Query!
State/province [65]
0
0
KwaZulu- Natal
Query!
Country [66]
0
0
South Africa
Query!
State/province [66]
0
0
Cape Town
Query!
Country [67]
0
0
South Africa
Query!
State/province [67]
0
0
Kempton Park
Query!
Country [68]
0
0
South Africa
Query!
State/province [68]
0
0
Pretoria
Query!
Country [69]
0
0
South Africa
Query!
State/province [69]
0
0
Stellenbosch
Query!
Country [70]
0
0
Spain
Query!
State/province [70]
0
0
A Coruña
Query!
Country [71]
0
0
Spain
Query!
State/province [71]
0
0
Elche
Query!
Country [72]
0
0
Spain
Query!
State/province [72]
0
0
Santander
Query!
Country [73]
0
0
Spain
Query!
State/province [73]
0
0
Santiago de Compostela
Query!
Country [74]
0
0
Spain
Query!
State/province [74]
0
0
Valencia
Query!
Country [75]
0
0
United Kingdom
Query!
State/province [75]
0
0
Essex
Query!
Country [76]
0
0
United Kingdom
Query!
State/province [76]
0
0
Middlesex
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
GlaxoSmithKline
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study (contRAst 3 [202018: NCT04134728]) is a Phase 3, randomized, multicenter, double-blind study to assess the safety and efficacy of GSK3196165 in combination with conventional (cs) DMARD[s]) or the treatment of adult participants with moderate to severe active rheumatoid arthritis (RA) who have had an inadequate response to biologic (b) DMARD[s]) and/or JAK inhibitors. The study will consist of a screening phase of up to 6 weeks followed by 24 week treatment phase in which participants will be randomized in ratio of 6:6:6:1:1:1 to GSK3196165 150 milligrams (mg) subcutaneously (SC) weekly,GSK3196165 90 mg SC weekly, sarilumab 200 mg SC every other week or placebo (three arms) respectively, all in combination with background csDMARD(s). At Week 12, participants in the three placebo arms will switch from placebo to active intervention (either GSK3196165 150 mg SC weekly, GSK3196165 90 mg SC weekly, or sarilumab 200 mg SC every other week). Participants who, in investigator's judgement will benefit from extended treatment with GSK3196165, may be included in the long-term extension study (contRAst X [209564: NCT04333147]). Any participant who does not transition into study 209564 will undergo a safety follow-up visit at Week 34 (corresponding to 12 weeks after the last potential dose of sarilumab, at Week 22).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04134728
Query!
Trial related presentations / publications
Query!
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed
Query!
Contacts
Principal investigator
Name
0
0
GSK Clinical Trials
Query!
Address
0
0
GlaxoSmithKline
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/ct2/show/NCT04134728
Download to PDF